Remission in schizophrenia: Results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population

Annals of General Psychiatry

Volumn 11, Issue , 2012, Pages

  Mosolov, Sergey N ^a   Potapov, Andrey V ^a   Ushakov, Uriy V ^b  

^a Moscow Research Institute of Psychiatry   (Russian Federation)

^b Moscow Outpatient Psychiatric Service 21   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ARTICLE; CATATONIC SCHIZOPHRENIA; CONSTIPATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIZZINESS; DRUG INDUCED HEADACHE; FOLLOW UP; GALACTORRHEA; HEBEPHRENIA; HUMAN; INSOMNIA; MENORRHAGIA; OBSERVATIONAL STUDY; OUTPATIENT; PARANOID SCHIZOPHRENIA; PHARMACOEPIDEMIOLOGY; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SECONDARY AMENORRHEA; SIDE EFFECT; SOCIAL INTERACTION; WEIGHT GAIN;

EID: 84855410422     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-11-1     Document Type: Article

References (32)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 1994, Washington DC: American Psychiatric Association, Fourth, American Psychiatric Association.
2. World Health Organization International Classification of Diseases 1994, St. Petersburg, Russia: World Health Organization, 10, World Health Organization.
3. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rational for consensus. Am J Psychiatry 2005, 162:441-449. 10.1176/appi.ajp.162.3.441, 15741458.
4. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
5. De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007, 92:68-73. 10.1016/j.schres.2007.01.010, 17336500.
6. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 2006, 40:738-745. 10.1016/j.jpsychires.2006.07.005, 16963087.
7. Wobrock T, Köhler J, Klein P, Falkai P. Achieving symptomatic remission in outpatients with schizophrenia - a naturalistic study with quetiapine. Acta Psychiatr Scand 2009, 120:120-128. 10.1111/j.1600-0447.2009.01379.x, 19392812.
8. Kane JM, Crandall DT, Marcus RN, Eudicone J, Pikalov A, Carson WH, Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007, 95:143-150. 10.1016/j.schres.2007.05.009, 17644313.
9. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59:22-23.
10. Mosolov SN. Scales of Psychometric Assessment of Schizophrenia and Conception of Positive and Negative Disorders 2001, Moscow, Russia: Novy Tsvet.
11. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
12. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994, 20:297-310.
13. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
14. Ware JJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
15. Luriya AR. Bases of Neuropsychology 1973, Moscow, Russia: Moscow State University.
16. Heaton RK, Pendleton MG. Use of neuropsychological test to predict adult patient everyday functioning. J Clin Psychol 1981, 49:807-821.
17. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation 1993, South Tucson, AZ: Neuropsychology Press, 2.
18. Lezak MD. Neuropsychological Assessment 1995, New York, NY: Oxford University Press, 3.
19. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry 2011, 24:114-121.
20. Gorwood P, Peusekens J, . on behalf of the EGOFORS initiative (European Group On Functional Outcomes Remission in Schizophrenia) Setting new standards in schizophrenia outcomes: Symptomatic remission 3 years before versus after the andreasen criteria. Eur Psychiatry on behalf of the EGOFORS initiative (European Group On Functional Outcomes Remission in Schizophrenia).
21. Li CT, Su TP, Chou YH, Lee YC, Liu ME, Ku HL, Shan IK, Bai YM. Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J Formos Med Assoc 2010, 109:378-388. 10.1016/S0929-6646(10)60066-6, 20497871.
22. Kurihara T, Kato M, Reverger R, Tirta IG. Remission in schizophrenia: a community-based 6-year follow-up study in Bali. Psychiatry Clin Neurosci 2011, 65:476-482. 10.1111/j.1440-1819.2011.02246.x, 21851456.
23. San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry 2007, 22:490-498. 10.1016/j.eurpsy.2007.06.005, 17904337.
24. Zimmermann J, Wolter A, Krischke NR, Preuss UW, Wobrock T, Falkai P. Response und Remission bei an Schizophrenie erkrankten Patienten. Nervenarzt 2011, 11:1440-1448.
25. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci 2010, 12:393-407. 3181974, 20954433.
26. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007, 94:99-106. 10.1016/j.schres.2006.12.032, 17499480.
27. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry 2009, 50:200-208. 10.1016/j.comppsych.2008.08.010, 19374962.
28. Sereysky MY. About the question of efficacy assessment of mental disease treatment. Proc Gannushkin Inst 1939, 4:9-25.
29. Zenevich GV. Remissions in Schizophrenia 1964, Leningrad, Russia: Meditsina.
30. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remision in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005, 77:215-227. 10.1016/j.schres.2005.03.006, 15908183.
31. Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG, . Risperidone Long-Acting Trial Investigators (R-LAI) Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2009, 24:574-583. 10.1002/hup.1067, 19790173, Risperidone Long-Acting Trial Investigators (R-LAI).
32. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Schizophr Res 2011, 133:42-46. 10.1016/j.schres.2011.09.018, 22000938.